The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274

Name:	us-gaap_AmortizationOfIntangibleAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

LICENSED TECHNOLOGY (Details Textual) - USD ($)	1 Months Ended	3 Months Ended
LICENSED TECHNOLOGY (Details Textual) - USD ($)	Nov. 04, 2018	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Finite-Lived Intangible Asset, Useful Life		20 years
Payable Due Licensor Non current		$ 20,000,000		$ 20,000,000
Amortization of Intangible Assets		1,345,000	$ 87,000
Payable Due Licensor Current		$ 10,000,000		$ 10,000,000
Abeona Therapeutics LLC [Member]
Finite-Lived Intangible Asset, Useful Life		20 years
REGENXBIO [Member] \| Licensing Agreements [Member]
Payable Due Licensor Non current	$ 20,000,000
Guaranteed Upfront Payment	20,000,000
Payment on Execution of Contracts	10,000,000
Annual Fees	100,000,000
Milestone Payment	60,000,000
Payable Due Licensor Current	$ 10,000,000